Hans Holger F.
- Country
- Germany
- Department
- Klinik für Gynäkologie
Research Overview
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
- Comparative Study of Sacituzumab Govitecan Versus Sacituzumab Govitecan Plus Pembrolizumab in Low-Risk Triple-Negative Early Breast Cancer
- Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer
Data & Insights
Has run more than one trial at 84 of 301 partner sites.
Specializations
Breast Cancer Specialization
This investigator specializes in early-stage breast cancer treatment, with particular emphasis on hormone receptor-positive (HR+) and HER2-negative breast cancer management.
- Triple-negative breast cancer interventions
- Hormone receptor-positive breast cancer therapy
- Early-stage disease management
The investigator focuses on innovative therapeutic approaches for various breast cancer subtypes.
Therapeutic Innovation
Active in developing personalized treatment strategies, incorporating both endocrine therapy and targeted therapeutic agents.
- Combined immunotherapy approaches
- Targeted biological therapies
- Dynamic marker-adjusted treatments
The research encompasses novel therapeutic combinations and personalized treatment protocols.
Clinical Outcomes
Focuses on improving disease-free survival through innovative treatment strategies in breast cancer care.
- Pathological complete response assessment
- Long-term survival outcomes
- Risk-stratified treatment approaches
Specializes in evaluating treatment efficacy through comprehensive clinical endpoints.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.